Market Overview

PTC Therapeutic, Roche Announce Joint Program in Spinal Muscular Atrophy Enters First Stage of Clinical Development

Related PTCT
Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT), the SMA Foundation, and Roche (OTC: RHHBY), announced today that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers. SMA is a genetic neuromuscular disorder that leads to muscle weakness and mobility impairment and is considered the leading genetic cause of death in infants and toddlers.   

See full press release

Posted-In: News Guidance Buybacks Global

 

Related Articles (RHHBY + PTCT)

Around the Web, We're Loving...

Get Benzinga's Newsletters